Capnopharm GmbH today announced it has entered into an asset purchase agreement to acquire all operating assets from Capnomed GmbH.

Founded in 2015, Capnomed has played an essential role in developing Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC™). PIPAC™ is a new, minimally-invasive method of treating peritoneal cancer delivering novel therapies to the entire affected tissue with precision and safety. Capnomed successfully introduced the medical device Capnopen™, the gold standard of laparoscopic nebulizers. Capnomed created a new market for intraperitoneal drug delivery, and developed PIPAC™’s ecosystem through academic collaborations, support for translational research and clinical studies, and unrestricted educational grants to peer-reviewed journals and scientific societies.

“One million patients develop peritoneal cancer globally every year. There is no truly effective therapy. Capnopharm’s vision is to change this and to shape the future of peritoneal cancer care”, said Ranjita Sahoo, PhD, Capnopharm’s Chief Scientific Officer. First randomized data presented at ASCO 2022 showed superiority of PIPAC™ with cisplatin and doxorubicin over systemic intravenous chemotherapy in platin-resistant ovarian cancer. Compared to intravenous chemotherapy, PIPAC™ had better response rate and improved quality of life with minimal morbidity¹. There are at least 40 further registered clinical trials evaluating PIPAC™’s safety and efficacy in various indications, including a collaborative PIPAC™ trial with the Capnopen™ in the USA². “Capnopharm will increasingly focus on next-generation strategies to overcome the challenges of existing therapies of peritoneal cancer. This will include repurposing and reformulating generic drugs, exploring nanotechnology, immunotherapy, cytolytic virotherapy and mRNA as new-era therapy platforms“, adds Dr. Sahoo.

“PIPAC™ will ultimately benefit to the patients. The acquisition of Capnomed’s assets will generate unique synergies at the crossroads of medical need, engineering and pharmaceutical sciences. This acquisition will further diversify our business, create operational synergies, facilitate market access and enhance Capnopharm’s value” said Prof. Marc A. Reymond, MD MBA, Capnopharm’s CEO.

¹ https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.5524

² https://www.clinicaltrials.gov/ct2/results?cond=&term=pipac&cntry=&state=&city=&dist=

About Capnopharm

Capnopharm GmbH (registered in Stuttgart, Germany, HRB 783092, is a privately-owned company with headquarters in Tübingen. Capnopharm’s products are sold in more than 40 countries through a combination of direct sales, distributors and a global footprint of 100+ leading cancer hospitals worldwide.

Disclaimer

Capnopen™ and PIPAC™ are protected trademarks detained by Capnopharm. Capnopen™ is CE-certified and registered in 40+ countries globally. To Capnopharm’s knowledge, no drug is approved for intraperitoneal delivery: PIPAC™ is an off-label procedure under the sole responsibility of the treating physician. The Capnopen™ device is not available for sale in the USA. Capnopharm GmbH has based forward-looking statements on its current assumptions, expectations and projections about future events. Unknown or unpredictable factors could have material adverse effects on future results, performance or achievements. In light of these risks, uncertainties, assumptions and factors, the forward-looking events discussed in this press release may not occur. Capnopharm GmbH is not under any obligation and does not intend to update or revise any of the forward-looking statements contained in this press release to reflect circumstances existing after the date of this press release and related conference call or to reflect the occurrence of future events.

For more information, please visit https://capnopharm.com

For company news, visit https://capnopharm.com/news

Investors can refer to https://capnopharm.com/investors